Login / Signup

The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany.

Peter BramlageSascha R TittelChristian WagnerKerstin KönigDirk RaddatzRosmarie Weber-LaufferDiether ErathJost HilgenbergCarsten SpiesThomas DanneMaximilian GablerJohannes FoerschLudwin LeyJochen Seufert
Published in: BMJ open diabetes research & care (2021)
Over time, empagliflozin is being prescribed to a broader patient range in routine practice, is usually added to existing antidiabetic regimens, and is increasingly used in combination with metformin, GLP-1 agonists and/or insulin. Empagliflozin had a beneficial effect on glycemic control, with no increase in hypoglycemia.
Keyphrases
  • glycemic control
  • clinical practice
  • type diabetes
  • blood glucose
  • weight loss
  • insulin resistance
  • healthcare
  • primary care
  • case report
  • metabolic syndrome
  • adipose tissue
  • quality improvement